



**Life Science REIT plc**  
(the "Company")

LEI: 213800RG7JNX7K8F7525

23 May 2024

### Annual General Meeting ("AGM") Results

The Company announces that at its Annual General Meeting held earlier today all the resolutions set out in the Notice of Annual General Meeting were passed. All resolutions were voted on by way of a poll. The results of the poll for each resolution were as follows:

Resolution	For		Against		Votes Withheld (No. of shares)
	No. of shares	%	No. of shares	%	
1. To receive and approve the annual report and financial statements	247,928,546	99.99%	14,663	0.01%	26,709
2. To receive and approve the Directors' remuneration report	247,684,045	99.97%	68,743	0.03%	217,130
3. To approve the Company's dividend payment policy	247,966,918	99.99%	3,000	0.01%	0
4. To re-elect Claire Boyle as a Director of the Company	229,246,645	95.31%	11,291,786	4.69%	7,431,487
5. To re-elect Sally Ann Forsyth as a Director of the Company	217,454,934	94.13%	13,561,582	5.87%	16,953,402
6. To re-elect Michael Taylor as a Director of the Company	238,575,348	99.18%	1,963,083	0.82%	7,431,487
7. To re-elect Richard Howell as a Director of the Company	238,572,783	99.18%	1,965,648	0.82%	7,431,487
8. To re-appoint Deloitte LLP as Auditor to the Company	247,897,047	99.97%	64,398	0.03%	8,473
9. To authorise the Audit and Risk Committee to determine the remuneration of the Auditor to the Company	247,916,572	99.98%	53,346	0.02%	0
10. To authorise the Directors to allot equity securities	222,777,035	89.84%	25,192,883	10.16%	0
11. To authorise the Directors to disapply pre-emption rights*	232,274,638	93.68%	15,668,571	6.32%	26,709
12. To authorise the Directors to					

12. To authorise the Directors to disapply pre-emption rights for the purposes of financing an acquisition or other capital investment*	231,970,086	93.58%	15,920,407	6.42%	79,425
13. To approve the purchase of the Company's own shares*	236,334,255	95.31%	11,635,663	4.69%	0
14. That a general meeting, other than an AGM, may be called on not less than 14 clear days' notice*	244,386,609	98.56%	3,580,744	1.44%	2,565

\*special resolution

#### NOTES:

1. All resolutions were passed.
2. Percentages have been rounded to two decimal places.
3. Proxy appointments which gave discretion to the Chair of the AGM have been included in the "For" total for the appropriate resolution.
4. Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.
5. A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.
6. The number of shares in issue at 6:00 pm. on 21 May 2024 was 350,000,000 ordinary shares, carrying one vote each, and at that time, the Company did not hold any shares in treasury.
7. The full text of the resolutions passed at the AGM can be found in the Notice of Annual General Meeting which is available on the Company's website at <https://lifesciencereit.co.uk/investors/shareholder-information/>

#### Enquiries:

**Link Company Matters Limited - Company Secretary**  
labs\_cosec@linkgroup.co.uk

**Ironstone Asset Management - Investment Adviser**  
Simon Farnsworth/ Joanna Waddingham via Buchanan below

**Panmure Gordon - Joint Corporate Broker**  
Alex Collins / Tom Scrivens +44 20 7886 2500

**Jefferies International Limited - Joint Corporate Broker**  
Tom Yeadon +44 20 7029 8000

**G10 Capital Limited - AIFM**  
Verity Morgan-Jones / Maria Baldwin +44 20 7397 5450

**Buchanan - Financial PR**  
Mark Court / Henry Wilson / Verity Parker +44 20 7466 5000  
LifeSciencereit@buchanan.uk.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how

RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGAJMATMTATBPI